Immunic hosts MS R&D Day, discusses vidofludimus calcium for relapsing and progressive MS

IMMUNIC, INC.

Immunic held a multiple sclerosis R&D Day on September 10, 2024.
Presentation focused on vidofludimus calcium (IMU-838) for relapsing and progressive multiple sclerosis.
No specific clinical or financial data from the presentation were disclosed in this 8-K.
The presentation was furnished as Exhibit 99.1 but is not summarized in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.